2025_11_03_vederlags_aksjer
Kalender
| Est. tid* | ||
| 2026-02-26 | 22:00 | Bokslutskommuniké 2025 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-08-04 | - | Extra Bolagsstämma 2025 |
| 2025-06-26 | - | Årsstämma |
| 2025-05-21 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2025-02-26 | - | Bokslutskommuniké 2024 |
| 2024-11-13 | - | Kvartalsrapport 2024-Q3 |
| 2024-10-10 | - | Extra Bolagsstämma 2024 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-30 | - | Split ONCIT 100:1 |
| 2024-05-29 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-11-14 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-22 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-15 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-24 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-29 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2022-04-28 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2022-01-06 | - | Extra Bolagsstämma 2022 |
| 2021-11-16 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-17 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-19 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-22 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2021-03-19 | - | Årsstämma |
| 2021-02-10 | - | Bokslutskommuniké 2020 |
| 2020-12-09 | - | Extra Bolagsstämma 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-19 | - | Kvartalsrapport 2020-Q1 |
| 2020-03-17 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2020-03-16 | - | Årsstämma |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-19 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-19 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | Kvartalsrapport 2019-Q1 |
| 2019-03-14 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2019-03-13 | - | Årsstämma |
| 2019-02-19 | - | Bokslutskommuniké 2018 |
| 2018-11-13 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-15 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2018-05-15 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-14 | - | Årsstämma |
| 2018-03-09 | - | Extra Bolagsstämma 2018 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-17 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-18 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-23 | - | Kvartalsrapport 2017-Q1 |
| 2017-03-23 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2017-03-22 | - | Årsstämma |
| 2016-06-22 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2016-06-21 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning ONCIT 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2025-11-03 08:55:36
Oslo, 3 November 2025: Reference is made to the stock exchange announcement
published by Oncoinvent ASA (the "Company") on 29 October 2025 regarding the
completion of the merger between the Company and the former Oncoinvent ASA (reg.
no. 995 764 458) ("Oncoinvent") (the "Merger").
In connection with completion of the Merger, the former shareholders of
Oncoinvent, including certain primary insiders of the Company and their close
associates, have today been allocated consideration shares in the Company. More
information about the allocation of consideration shares is included in the
Prospectus published on 28 October 2025.
Please see the attached forms for further details on the allocation of
consideration shares in the Merger to the Company's primary insiders and their
close associates.
For more information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
About Oncoinvent ASA
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial is currently ongoing
in the US, UK and Europe. Early clinical efficacy data are highly encouraging,
and no serious toxicity or safety concerns have been reported to date. The
Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art
manufacturing facility to produce drug products for clinical trials in Nydalen,
Oslo. Oncoinvent is listed on Euronext Oslo Børs.
This information is subject to the disclosure requirements in article 19 of
Regulation EU 596/2014 (the EU Market Abuse Regulation) and Section 5-12 of the
Norwegian Securities Trading Act.